Livforsakringsbolaget Skandia, Omsesidigt 13F: Cuts LLY Stake by $2.2M

Livforsakringsbolaget Skandia trimmed its stake in Eli Lilly and Company (NYSE:LLY) by 4.4% during the recent quarter, according to a Form 13F filing submitted to the Securities and Exchange Commission on October 21, 2026.

The institutional investor sold 1,920 shares of the drugmaker, bringing its total ownership to 42,010 shares. That remaining position was valued at approximately $48,608,931 at the time of the filing, down from its prior holding of 43,930 shares.

LLY Eli Lilly and Company

$1,272.20 ▲ +18.33% year to date

1M 3M YTD

Daily close · Oct 21, 2026

Other Institutional Activity in Eli Lilly and Company

Other large investors adjusted their positions in Eli Lilly around the same time. Ninety One UK trimmed its holdings significantly, cutting 225,437 shares to finish with 344,968 shares worth about $399,155,581 after a 39.5% reduction. PensionDanmark Pensionsforsikringsaktieselskab reduced its stake by 2.4%, parting with 3,570 shares to hold 145,819 shares valued at roughly $168,724,249. On the buying side, James Hambro & Partners grew its holdings by 507 shares, ending with 1,831 shares worth about $2,123,428 after a 38.3% increase. Annex Advisory Services expanded its position aggressively, adding 29,346 shares for a 765.2% jump to hold 33,181 shares valued at about $38,393,602. Focus Financial Network also added to its stake, boosting its holdings by 632 shares to finish with 7,646 shares worth roughly $8,847,034 after a 9.0% increase.

Eli Lilly and Company Stock Down 0.9%

Eli Lilly shares recently traded around $1,272.20 as of October 22, 2026, sitting about equal to the $1,270.75 close recorded on the filing date. The stock trades comfortably above its 50-day moving average of $1,183.59 and its 200-day moving average of $1,082.90. Over the past year, the shares have changed hands between a low of $806.02 and a high of $1,311.75.

Recent Earnings

Eli Lilly reported trailing-twelve-month revenue of $79.67 billion alongside earnings of $29.79 per share. The healthcare giant posted a net profit margin of 33.5% and a return on equity of 102.3%, with year-over-year revenue growth reaching 47.7%. The company's next quarterly earnings update is scheduled for October 29, 2026.

Dividend

The company pays an annual dividend rate of $6.92 per share, which translates to a dividend yield of 0.54% based on recent trading levels. That payout is supported by a dividend payout ratio of 21.7%.

Insider Buying and Selling at Eli Lilly and Company

Company insiders completed several share sales over the summer months before the filing was made public. General Counsel Anat Hakim sold 5,000 shares on August 7, 2026, at an average price of $1,190.00 for a total value of $5,950,000. Officer Donald A. Zakrowski sold 2,000 shares on August 10, 2026, at $1,185.01 per share, totaling $2,370,020. Later, on August 17, 2026, Officer Patrik Jonsson parted with 6,500 shares at an average price of $1,175.10, raising $7,638,150.

Analysts Set New Price Targets

Wall Street research firms remain largely upbeat on the drugmaker's outlook. JP Morgan maintained its Overweight rating while lifting its target to $1,500.00 on September 28, 2026. Morgan Stanley kept an Overweight rating on October 7, 2026, moving its target from $1,419.00 to $1,430.00. Cantor Fitzgerald maintained an Overweight rating and raised its target from $1,410.00 to $1,440.00 on October 8, 2026. RBC Capital reiterated its Outperform rating with a $1,500.00 target on October 12, 2026. Leerink Partners kept an Outperform rating while nudging its target from $1,309.00 to $1,316.00 on October 21, 2026. Overall, the stock carries a consensus buy rating and a mean price target of $1,331.55 across 30 analyst opinions.

About Eli Lilly and Company

Eli Lilly and Company is an Indianapolis-based pharmaceutical firm that discovers, develops, and sells human medicines globally. The company focuses on major treatment areas including diabetes, oncology, immunology, and neuroscience, bringing core therapies to patients across the United States, Europe, Asia, and other international markets.

Bottom Line

Institutional investors continue to fine-tune their portfolios around Eli Lilly as the company prepares to deliver its next earnings report on October 29, 2026. Market watchers will look to that upcoming update for fresh details on drug demand and revenue momentum.